key: cord-0900444-s94pvm30
authors: Soremekun, Opeyemi S; Omolabi, Kehinde F; Adewumi, Adeniyi T; Soliman, Mahmoud ES
title: Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective
date: 2020-11-09
journal: Future science OA
DOI: 10.2144/fsoa-2020-0079
sha: 93f9922e007b1f53a488e092799d737114c7b5c5
doc_id: 900444
cord_uid: s94pvm30

Aim: As coronavirus (CoV) disease 2019-associated pneumonia spreads globally, there has been an urgent need to combat the spread and develop vaccines. Materials & methods: We used an integrated computational algorithm to explore the binding mechanism of TMC-310911/ritonavir (RVT) with SARS-CoV-2 and SARS-CoV main proteases. Results: RVT and TMC-310911 had favorable interactions with the proteases, and these high interactions are facilitated by some significant residues such as Asn133, Gly195 and Gln192. Our study further implicated two important rings in the structure of RVT as a possible chemical culprit in its therapeutic activity. Conclusion: Although there are conflicting clinical results on the therapeutic potency of RVT in the treatment of coronavirus disease 2019, our findings provided molecular insight into the binding mechanism of TMC-310911 and RVT with SARS-CoV-2 and SARS-CoV main proteases.

been reported to have helped patients overcome the infection through boosting their immune system [8] ; however, currently, no vaccines or drugs are available for the treatment of this disease [11] . The global spread of COVID-19 and the absence of vaccines or drugs have necessitated the demand of drug repurposing. Crucial proteins that have gained attention in the development of potential COVID-19 drugs include SARS-CoV-2 main proteases (COV), RNA-dependent RNA polymerase, RNA binding N terminal domain of nucleocapsid protein, viral ion channel, 2 O-ribosemethyltransferase and human angiotensin-converting enzyme 2 receptor [12] [13] [14] . Several existing drugs such as remdesivir, chloroquine, hydroxychloroquine, camostatmesylate, lopinavir, etc., have been considered for targeting different phases of the virus life cycle.

Ritonavir (RVT) is an antiretroviral drug used in the treatment of advanced HIV, it is used as a protease inhibitor and also used to boost other protease inhibitors [15] . It is sometimes used in combination with antiretroviral drugs such as nucleotide reverse transcriptase inhibitor or nucleoside [15, 16] . An in vivo study found a reduced risk of mortality and hypoxia in 41 SARS-CoV patients who were administered a combination of lopinavir/RVT and ribavirin, when compared with controls administered ribavirin alone [17, 18] . A different study from Korea revealed that there was a significant reduction in CoV titers upon lopinavir-RVT administration [19] . Contradictory, a combination of lopinavir and RVT was investigated in a controlled trial study, patients with COVID-19 were administered either lopinavir-RVT 400/100 mg orally twice daily plus standard of care, or standard of care alone, there was no therapeutic benefit observed upon administration [20] . There are at least three randomized clinical trials currently been carried out to determine the therapeutic efficacy of a combination of lopinavir and RVT [21] . Similarly, ASC-09 also referred to as TMC-310911 is a protease inhibitor that is still under clinical studies to treat HIV infection. It has shown in vitro activity against the HIV strains that have developed resistance to other protease inhibitors [22] . There is currently an ongoing clinical trial that seeks to evaluate the safety and efficiency of a combination of ASC09/RVT on CoV infection (clinicaltrials.gov/ct2/show/NCT04261907) [23] .

In this study, we repurposed two existing HIV-protease inhibitors RVT and TMC-310911 (ASC09) to target SARS-CoV-2 main protease (COV) and SARS-CoV main protease (SARS) to explore their possible mode of inhibition.

The starting structures of COV and SARS were obtained from Protein Data Bank with PDB ID 6LU7 [24] and 5N19 [25] , respectively. Cocrystalized molecules identified with the proteins were deleted and the addition of missing residues was performed using modeler [26] . RVT and TMC-310911 were retrieved from PubChem, the 2D structures were converted to 3D structures and optimized using B3LYP/6-311++G(d,p) [27] level of Gaussian16 [28] . The final structures were saved as Mol2 files. Molecular docking of the proteases with the inhibitors was carried out using AutoDock Vina [29] inbuilt in UCSF chimera [30] . AutoDock Vina is software developed by O Trott of Molecular Graphics Laboratory at the Scripps Research Institute [29] . Validation of the docking results was carried out by redocking multiple times. COV and SARS were prepared for docking by the removal of water and cocrystallized ligands. Hydrogens were added and optimization of the hydrogen-bonding network was carried out with the aid of Avogadro software [31] . The clean COV and SARS structures were saved for docking. During the docking process, we allotted partial chargers called Gasteiger to the ligands. The AutoDock [32] GUI provided by the Molecular Graphics Laboratory tool was utilized to define the AutoDock atomic types [33] . The defined parameter grid dimensions used in docking TMC-310911 with COV and SARS were center (x = -17.56, Y = 0.29 and Z = -21.46) and size (X = 16.00, Y = 16.06 and Z = 13.19), while center (x = -17.19, Y = 0.44 and Z = -21.95) and size (X = 14.21, Y = 16.58 and Z = 11.86) were used for docking RVT with COV and SARS. The remaining values were set to default. Molecular dynamic simulation run was carried out with the aid of Amber 19 [34] software using the FF14SB force field [35] . The general Amber force field and restrained electrostatic potential were used in describing the atomic charges of RVT and TMC-310911. Leap variant present in Amber 19 was used for system neutralization and hydrogen atoms addition [36] . The system was solvated with an orthorhombic box of TIP3P water molecules surrounding all protein atoms at a distance of 9Å [27] . System minimization was carried out first with a 2000 step minimization utilizing a restraint potential of 500 kcal/mol. Second, we used a 10,000-step full minimization process without restraint. Afterwards, the system was gradually heated at a temperature of 0-300 k at 50 ps. The system solutes are kept at a potential harmonic restraint of 10 kcal mol -1Å-2 and collision frequency of 1.0 ps -1 . Next, the equilibration of 500 ps was carried out. The temperature and pressure were kept constant at 300 k and 1 bar (isobaric-isothermal ensemble, constant temperature and pressure using Berendsen barostat). Each step of the simulation was run for 2 fs and an single-precision floating-point precision model was adopted. The simulations were kept at constant temperature and pressure, and Langevin thermostat at collision frequency of 1.0 ps -2 . Six systems were set up for molecular dynamics (MD) simulations. These systems are unbound COV, COV bound to TMC-310911 (COV TMC), COV bound to RVT (COV RVT), unbound SARS, SARS bound to TMC-310911 (SARS TMC) and SARS bound to RVT (SARS RVT). PTRAJ variant of Amber 19 was adopted for further analysis which included root mean square deviation (RMSD) and radius of gyration (RoG) [37] . The data plots were then made with ORIGIN analytical tool and visualization was done using UCSF Chimera [38] .

The molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) [39] was employed in the estimation of the binding strength in the COV TMC, COV RVT, SARS TMC and SARS RVT. MM/PBSA is described as an end-point energy estimation used in the calculation of binding mode of ligands and their corresponding protein target. MM/PBSA is described as:

G gas represents the total gas-phase energy calculated by intermolecular energy ( E int ), electrostatic energy ( E elel ) and van der Waals energy ( E vdW ). G sol represents the solvation energy, T S represents entropy change.

G ele,sol(GB) describes polar desolvation energy while G np,sol describes the nonpolar desolvation energy. The γ is the surface tension proportionality constant and is set to 0.0072 kcal mol -1Å-2 , β is a constant equal to 0 and SASA is the solvent-accessible surface area (Å 2 ).

RVT and TMC-310911 (TMC) like any other HIV protease inhibitors work by inhibiting proteases found in the liver, intestine and other places [40, 41] . The binding of RVT to the active site of HIV proteases prevents cleavage of the viral polyproteins subsequently leading to inactive and noninfectious viral components [15] . Similarly, TMC-310911 works following this pharmacokinetic and pharmacodynamic route [22] . Therefore, we explored the mechanism of inhibition and structural perturbative effect of RVT and TMC-3410911 binding to COV and SARS. MM/PBSA has been widely employed in the drug development and computer-aided drug designs space, it estimates the binding strength between an inhibitor and a protein [42, 43] . COV RVT, SARS RVT, COV TMC and SARS TMC had binding free energy of -29.46, -32.34, -32.29 and -47.19 kcal/mol, respectively. Findings from this analysis revealed that the RVT and TMC-310911 had a favorable binding interaction with the COV and SARS (Table 1) . Furthermore, from Table 1 , it is observed that the various free energy components facilitated this strong interaction. Most especially the electrostatic and van der Waals interactions observed in the gas phase of COV TMC and SARS TMC.

We used a representative snapshot and active site residue decomposition to further explore the time-wise bond interaction occurring between major residues in the active site of COV/SARS and TMC-310911/RVT. In the COV RVT system, Asn133, Gly195 and Gln192 elicited hydrogen bond interactions, Phe185 formed π-sulphur interaction with the S atom present in RVT ring ( Figure 1A) . The decomposition of this interaction also showed that favorable energy was contributed by residues possessing energy contributions greater than -0.5 kcal/mol. Ala194, which formed a pi-alkyl bond with RVT, contributed the highest total, van der Waal, and electrostatic energies to the overall binding ( Figure 1B) . Decomposing the active site residues of the SARS RVT system revealed that Met49 and Gln189 contributed the most to the overall binding of RVT to SARS. In comparison to the COV RVT system, SARS RVT had higher G bind , this could be as a result of the high sigma bond formed by Pro168, Met49 and Cys145 ( Figure 1C ). Binding of TMC-310911 to COV and SARS demonstrated an overall favorable binding when compared with RVT binding. This is evident by the high energy decomposition of the individual active site residues. Asn142 and Asp187 elicited a high hydrogen bond, while Ser46, Thr45 and Met 49 formed a pi-alkyl bond with TMC-310911 ( Figure 2 ).

To further explore the possible mechanism of the action of RVT on SARS-CoV-2 main protease, we examined the interaction trend of two important rings in RVT in the course of the simulation run. Interestingly, these two rings formed strong interaction with residues embedded inside the active site. These interactions sequestered RVT deeper into the active site (Figure 3) . Figure 4B ).

Sequence similarity is described as a measure of the empirical relationship that exists between sequences, it establishes the propensity of sequences evolving from a common ancestor. Joshi et al. have demonstrated that COV has higher sequence similarity with SARS when compared with MERS-CoV main protease [44] . In this study, RVT and TMC-310911 were repurposed to bind with COV and SARS. Although there are conflicting results on the therapeutic effectiveness of RVT and TMC-310911 in the treatment of COVID-19. For instance, in a clinical trial study, the combination of lopinavir and RVT was investigated in a controlled trial study, patients with COVID-19 were administered either lopinavir-RVT 400/100 mg orally twice daily plus standard of care or standard of care alone, there was no therapeutic benefit observed upon administration [20] . RMSD is a commonly used quantitative parameter employed to estimate the similarity between two superimposed structures. RMSD can be computed for different components of a biomolecule. In MD simulation, the RMSD is often calculated for the Cα of the entire protein structure, for example, those found in the loop, active site and perhaps transmembrane helices. Many types of researches have used RMSD as a measure of protein stability and equilibration. RMSF is defined as the measure of the atomic displacement of a single or a group of atoms relative to the starting or reference structures, averaged over the number of atoms [45] . RoG is a function used to define the distribution of atoms of a protein around its axis. The most significant parameter used in the prediction of protein compactness is RoG [46] . Insight from RMSD, RMSF [47] . Upon binding of RVT to SARS-CoV-2 main protease, the structural compactness of the COV TMC, COV RVT system were lesser than that of the COV system, similar trend was observed in the SARS TMC and SARS RVT systems.

Presently, there is no available clinical antiviral compound (or drug) with therapeutic evidence that cures COVID-19 and several strategies are being considered to treat this disease, including repurposing drugs that are active against SARS-CoV and MERS-CoV. Other strategies such as inhibitors of viral and host protease, host-directed therapies and the use of antibodies are being currently explored. In this study, we explored the inhibitory effect of RVT and TMC-310911 on COV and SARS. Results from this study revealed that RVT and TMC-310911 had strong binding interaction with COV and SARS. Two rings were found to be crucial to the binding of RVT to COV and SARS. These two rings could be further explored in the development of inhibitors specifically tailored to target SARS-CoV-2 proteases.

We employed integrated computational algorithms and force field protein-ligand dynamics calculations to repurpose and explore the possible mechanism of inhibition of RVT and TMC-310911 upon binding to COV and SARS. Findings from this study can facilitate a new frontier in structure-based design of highly effective and tailored inhibitors of SARS-CoV-2 main protease in the treatment of CoV infections.

• Upon ritonavir (RVT) binding to SARS coronavirus 2 (SARS-CoV-2) main protease (COV), Asn133, Gly195 and Gln192 elicited hydrogen bond interactions, while Phe185 formed π-sulphur interaction with the S atom present in the RVT ring. • RVT and TMC-310911 had strong interactions with the proteases, and these high interactions are facilitated by some significant residues found in their active site. • Despite having similar residues in their active sites, COV elicited ligand interactions with dissimilar residues as SARS-CoV protease. • Two rings were found to be crucial to the binding of RVT to COV and SARS-CoV main proteases. 

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecomm ons.org/licenses/by/4.0/

Molecular evolution of human coronavirus genomes

Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management

MERS-CoV as an emerging respiratory illness: a review of prevention methods

Coronavirus envelope protein: current knowledge

Commentary genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Open reading frame 8a of the human severe acute respiratory syndrome coronavirus not only promotes viral replication but also induces apoptosis

Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance. World Health Organization

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Coronavirus disease COVID-2019

SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Biotech start-ups hit by coronavirus work stoppages

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Recent advances and uses of grape flavonoids as nutraceuticals

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective

Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin

Lopinavir/ritonavir: a review of its use in the management of HIV infection

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses

Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors

Evaluating and comparing the safety and efficiency of ASC09/ritonavir and lopinavir/ritonavir for novel coronavirus infection. Identifier NCT04261907. US National Library of Medicine

Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv

α-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment

Comparative protein structure modeling using MODELLER

Comparison of simple potential functions for simulating liquid water

Gaussian quantum information

Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity

UCSF chimera, MODELLER, and IMP: an integrated modeling system

Avogadro: an advanced semantic chemical editor, visualization, and analysis platform

Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazoline derivatives

Python: a programming language for software integration and development

The Amber biomolecular simulation programs

An overview of the Amber biomolecular simulation package

CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data

UCSF chimera: a visualization system for exploratory research and analysis

Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models

Protease inhibitor resistance update: where are we now?

Fifteen years of HIV protease inhibitors: raising the barrier to resistance

Drug promiscuity: exploring the polypharmacology potential of 1, 3, 6-trisubstituted 1, 4-diazepane-7-ones as an inhibitor of the 'god father' of immune checkpoint

Across the blood-brain barrier: neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer's disease using bioinformatics and computational tools

Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease

Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis

Recruiting monomer for dimer formation: resolving the antagonistic mechanisms of novel immune check point inhibitors against programmed death ligand-1 in cancer immunotherapy

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors